CME reports Results for the third quarter and nine months ended September 30, 2014

THIRD QUARTER
- Net revenues of US$ 140.1 million -
- OIBDA of US$ 2.9 million -


NINE MONTHS
- Net revenues of US$ 496.3 million -
- OIBDA of US$ 42.2 million -

Net revenues for the third quarter ended September 30, 2014 were US$ 140.1 million compared to US$ 131.0 million for the same period in 2013. OIBDA (as defined below) for the third quarter ended September 30, 2014 was US$ 2.9 million compared to US$ (31.6) million in 2013. Operating loss for the three months ended September 30, 2014 was US$ (8.6) million compared to US$ (43.9) million in 2013. Net loss for the three months ended September 30, 2014 was US$ (52.5) million compared to US$ (23.3) million in 2013. Fully diluted loss per share attributable to CME for the three months ended September 30,
2014 was US$ (0.38) compared to US$ (0.18) in 2013.

Net revenues for the nine months ended September 30, 2014 were US$ 496.3 million compared to US$ 437.2 million for the same period in 2013. OIBDA for the nine months ended September 30, 2014 was US$ 42.2 million compared to US$ (44.3) million in 2013. Operating loss for the nine months ended September 30, 2014 was US$ (0.4) million compared to US$ (83.4) million in 2013. Net loss for the nine months ended September 30, 2014 was US$ (153.6) million compared to US$ (173.3) million in 2013. Fully diluted loss per
share attributable to CME for the nine months ended September 30, 2014 was US$ (1.12) compared to US$ (1.48) in 2013.

OIBDA, which includes amortization and impairment of program rights, is determined as operating income / (loss) before depreciation, amortization of intangible assets and impairments of assets and certain unusual or infrequent items that are not considered by our chief operating decision makers when evaluating our performance as defined in "Segment Data and Non-GAAP Financial Measures" below. Costs charged in arriving at OIBDA during the nine months ended September 30, 2014 exclude a one-off charge of US$ 6.9 million accrued in the second quarter in respect of a fine the competition agency in Slovenia is seeking to impose relating to operations there prior to 2012. We have appealed the decision.

Michael Del Nin, Co-Chief Executive Officer, commented: "This quarter's financial results continue to reflect the strong turnaround in our operations. In fact, as a whole, this is our most impressive quarter so far this year."

Christoph Mainusch, Co-Chief Executive Officer, added: "The performance of our fall schedule demonstrates the strength of our brands and content, and positions us very well for the fourth quarter and as we head into negotiations for advertising spending commitments from clients for 2015."

Consolidated Results for the Three Months Ended September 30, 2014

Net revenues for the three months ended September 30, 2014 were US$ 140.1 million compared to US$ 131.0 million for the three months ended September 30, 2013. Operating loss for the three months ended September 30, 2014 was US$ (8.6) million compared to US$ (43.9) million for the three months ended September 30, 2013. Net loss for the three months ended September 30, 2014 was US$ (52.5) million compared to US$ (23.3) million for the three months ended September 30, 2013. Fully diluted loss per share attributable to CME for the three months ended September 30, 2014 was US$ (0.38) compared to US$ (0.18) for the three months ended September 30, 2013.

OIBDA for the three months ended September 30, 2014 was US$ 2.9 million compared to US$ (31.6) million in the same period ended September 30, 2013. OIBDA margin1 for the three months ended September 30, 2014 was 2.1% compared to (24.1)% for the three months ended September 30, 2013.

Headline consolidated results for the three months ended September 30, 2014 and September 30, 2013 were:


(US$ 000's)For the Three Months Ended September 30,
(unaudited)2014 2013 % Actual % Lfl2
Net revenues$140,149 $130,988 7.0% 9.8%
OIBDA2,937 (31,585) NM3 NM3
Operating loss(8,640) (43,933) 80.3% 79.9%
Net loss(52,482) (23,273) (125.5)% (132.7)%
Fully diluted loss per share$(0.38) $(0.18) (111.1)% (140.0)%

Consolidated Results for the Nine Months Ended September 30, 2014

Net revenues for the nine months ended September 30, 2014 were US$ 496.3 million compared to US$ 437.2 million for the nine months ended September 30, 2013. Operating loss for the nine months ended September 30, 2014, which includes a charge of US$ 6.9 million for a fine the competition agency in Slovenia is seeking to impose, was US$ (0.4) million compared to US$ (83.4) million for the nine months ended September 30, 2013. Net loss for the nine months ended September 30, 2014 was US$ (153.6) million compared to US$ (173.3) million in the nine months ended September 30, 2013. Fully diluted loss per share attributable to CME for the nine months ended September 30, 2014 was US$ (1.12) compared to US$ (1.48) in the nine months ended September 30, 2013.

OIBDA for the nine months ended September 30, 2014 was US$ 42.2 million compared to US$ (44.3) million in the same period ended September 30, 2013. OIBDA margin for the nine months ended September 30, 2014 was 8.5% compared to (10.1)% for the nine months ended September 30, 2013.

Headline consolidated results for the nine months ended September 30, 2014 and September 30, 2013 were:

(US$ 000's)For the Nine Months Ended September 30,
(unaudited)2014 2013 % Actual % Lfl2
Net revenues$496,256 $437,214 13.5% 12.1%
OIBDA42,191 (44,339) NM3 NM3
Operating loss(377) (83,387) NM3 NM3
Net loss(153,621) (173,324) 11.4% 10.6%
Fully diluted loss per share$(1.12) $(1.48) 24.3% 27.1%

1OIBDA margin is defined as the ratio of OIBDA to net revenues as defined in "Segment Data and Non-GAAP Financial Measures" below. 2 % Lfl (like-for-like) variance reflects the impact of applying the current period average exchange rates to the prior period revenues and costs.
3Number is not meaningful.

Teleconference and Audio Webcast Details

CME will host a teleconference and audio webcast to discuss its third quarter results on Thursday, October 30, 2014 at 10 a.m. New York time (2 p.m. London and 3 p.m. Prague time). The audio webcast and teleconference will refer to presentation slides which will be available on CME's website at www.cme.net prior to the call.

To access the teleconference, U.S. and international callers may dial +1-785-424-1835 ten minutes prior to the start time and reference passcode CETVQ314. The conference call will be audio webcasted via www.cme.net. It can be heard on iPads, iPhones and a range of devices supporting Android and Windows operating systems.

A digital audio replay will be available for two weeks following the call at www.cme.net.

CME will post the results for the nine months ended September 30, 2014 for its wholly-owned subsidiary CET 21 spol. s r.o. at www.cme.net by Friday, December 12, 2014.